D.E. Shaw & Co’s AstraZeneca AZN Stock Holding History

D.E. Shaw & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,450	Closed	-$1.14M	–	4590
2025 Q3	$1.14M	Buy	+7,450	New	+$1.13M	﹤0.01%	3378
2022 Q1	–	Sell	-44,520	Closed	-$5.19M	–	5520
2021 Q4	$5.19M	Hold	44,520	–	–	﹤0.01%	2334
2021 Q3	$5.35M	Hold	44,520	–	–	﹤0.01%	2054
2021 Q2	$5.33M	Buy	+44,520	New	+$4.88M	﹤0.01%	1974
2020 Q3	–	Sell	-32,100	Closed	-$3.4M	–	3833
2020 Q2	$3.4M	Hold	32,100	–	–	﹤0.01%	1978
2020 Q1	$2.87M	Hold	32,100	–	–	﹤0.01%	1893
2019 Q4	$3.2M	Buy	+32,100	New	+$3.02M	﹤0.01%	2096
2016 Q1	–	Sell	-71,000	Closed	-$4.82M	–	3412
2015 Q4	$4.82M	Hold	71,000	–	–	0.01%	1432
2015 Q3	$4.52M	Hold	71,000	–	–	0.01%	1476
2015 Q2	$4.52M	Sell	71,000 -30,000	-30%	-$2.05M	0.01%	1547
2015 Q1	$6.91M	Sell	101,000 -152,400	-60%	-$10.6M	0.01%	1177
2014 Q4	$17.8M	Buy	253,400 +30,000	+13%	+$2.15M	0.02%	765
2014 Q3	$16M	Hold	223,400	–	–	0.02%	813
2014 Q2	$16.6M	Buy	223,400 +35,100	+19%	+$2.54M	0.02%	801
2014 Q1	$12.2M	Buy	188,300 +174,700	+1,285%	+$11.3M	0.02%	924
2013 Q4	$807K	Hold	13,600	–	–	﹤0.01%	3351
2013 Q3	$706K	Hold	13,600	–	–	﹤0.01%	3336
2013 Q2	$643K	Buy	+13,600	New	+$693K	﹤0.01%	3058

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

D.E. Shaw & Co's AZN Position: Q2 2026 in Review

D.E. Shaw & Co increased its AstraZeneca (AZN) stake by 4,277% in Q2 2026, buying an estimated $201M and bringing the position to 1,094,593 shares worth $208M. The position accounts for 0.1% of the portfolio, ranked #214.

D.E. Shaw & Co first reported a position in AZN in Q2 2013 and has held it in 42 quarters since. The position peaked at $316M in Q4 2024. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

D.E. Shaw & Co held 1,094,593 shares of AstraZeneca worth $208M as of Q2 2026.
D.E. Shaw & Co bought 1,069,588 AstraZeneca shares in Q2 2026, an estimated $201M.
AstraZeneca made up 0.1% of D.E. Shaw & Co's portfolio in Q2 2026, its #214 holding.
D.E. Shaw & Co first reported a position in AstraZeneca in Q2 2013 and has held it in 42 quarters since.
D.E. Shaw & Co's AstraZeneca position peaked at $316M in Q4 2024.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.